Relationship between Epithelial-to-Mesenchymal Transition and Tumor-Associated Macrophages in Colorectal Liver Metastases

Int J Mol Sci. 2022 Dec 19;23(24):16197. doi: 10.3390/ijms232416197.

Abstract

The liver is the most common metastatic site in colorectal cancer (CRC) patients. Indeed, 25-30% of the cases develop colorectal liver metastasis (CLM), showing an extremely poor 5-year survival rate and resistance to conventional anticancer therapies. Tumor-associated macrophages (TAMs) provide a nurturing microenvironment for CRC metastasis, promoting epithelial-to-mesenchymal transition (EMT) through the TGF-β signaling pathway, thus driving tumor cells to acquire mesenchymal properties that allow them to migrate from the primary tumor and invade the new metastatic site. EMT is known to contribute to the disruption of blood vessel integrity and the generation of circulating tumor cells (CTCs), thus being closely related to high metastatic potential in numerous solid cancers. Despite the fact that it is well-recognized that the crosstalk between tumor cells and the inflammatory microenvironment is crucial in the EMT process, the association between the EMT and the role of TAMs is still poorly understood. In this review, we elaborated on the role that TAMs exert in the induction of EMT during CLM development. Since TAMs are the major source of TGF-β in the liver, we also focused on novel insights into their role in TGF-β-induced EMT.

Keywords: TGF-β signaling; colorectal liver metastases; epithelial-to-mesenchymal transition; tumor-associated macrophages.

Publication types

  • Review

MeSH terms

  • Cell Line, Tumor
  • Colorectal Neoplasms* / pathology
  • Epithelial-Mesenchymal Transition
  • Humans
  • Liver Neoplasms* / metabolism
  • Transforming Growth Factor beta / metabolism
  • Tumor Microenvironment
  • Tumor-Associated Macrophages / metabolism

Substances

  • Transforming Growth Factor beta

Grants and funding

This work was supported by “Bando Ricerca Finalizzata 2018 of the Italian Ministry of Health” (ID = RF-2018-12367150). The funding agency had no role in the design of the study or collection and analysis of data.